Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

Diagnostic cholecystokinetic agent (synthetic CCK octapeptide)

Sincalide

Kinevac

Dosage form
Tablet
Available strengths
5 mcg/vial (1 mcg/mL after reconstitution)
Drug class
Diagnostic cholecystokinetic agent (synthetic CCK octapeptide)
Common brand
Kinevac

Clinical overview. Sincalide (Kinevac) is a synthetic form of cholecystokinin given by intravenous injection to stimulate gallbladder contraction during gallbladder imaging, to test pancreatic function alongside secretin, and to help relieve postoperative bowel slowdown. It is administered by trained healthcare staff during a diagnostic procedure rather than taken at home. Effects are typically mild and short-lived, most often abdominal cramping, nausea, or flushing, though rare allergic reactions can occur.

Indication

Common therapeutic uses

  • Sincalide is used to stimulate gallbladder contraction during cholecystography (gallbladder imaging), allowing visualization of the gallbladder and bile ducts and collection of bile for analysis.
  • Sincalide is used together with secretin (the Secretin-Kinevac test) to stimulate pancreatic secretions for analysis, such as in evaluating suspected pancreatic cancer.
  • Sincalide is used to relieve postoperative ileus that is not complicated by inflammation, tumors, or other obstruction of the digestive tract.
  • Sincalide is used to decrease the transit time of contrast media through the small bowel during radiologic studies.

Pregnancy

Risk assessment and monitoring considerations

  • The safety of sincalide has not been established in pregnant women.
  • Because sincalide affects smooth muscle, it may theoretically trigger spontaneous abortion or premature labour in pregnant patients, so it should be used cautiously and only when clinically necessary.

Breastfeeding

Infant exposure considerations

  • It is not known whether sincalide is excreted into human breast milk.
  • Because many drugs pass into breast milk, caution should be exercised when giving sincalide to a breastfeeding patient.

Geriatrics

Dosing and tolerability considerations

  • Clinical studies of sincalide did not include enough patients aged 65 and older to determine whether they respond differently than younger patients.

Pediatrics

Use in children and adolescents

  • The safety and efficacy of sincalide in children have not been established, so it is not authorized for pediatric use in Canada.

Dosage & Administration

Practical dosing and administration

  • For gallbladder contraction during cholecystography, sincalide is given as a slow intravenous injection over 30 to 60 seconds, dosed by body weight; a second, higher dose may be given if gallbladder contraction is not satisfactory after 15 minutes.
  • For the Secretin-Kinevac test of pancreatic function, sincalide is given as a slow intravenous infusion over 30 minutes, starting 30 minutes after a separate secretin infusion is begun.
  • For postoperative ileus or to speed transit of contrast through the small bowel, sincalide is injected over 30 to 60 seconds; the dose may be repeated or increased at intervals if the initial response is inadequate, up to a defined maximum number of doses.
  • After reconstitution with sterile water for injection, the solution may be stored under refrigeration for up to 24 hours, after which any unused portion must be discarded.
  • Sincalide is intended for single-procedure administration by trained personnel and is not intended for ongoing self-administration.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • Symptoms of sincalide overdose are typically mild and short-lived gastrointestinal effects, including abdominal discomfort, cramping, nausea, vomiting, and diarrhea.
  • Dizziness and flushing may also occur with an excessive dose.
  • Overdose symptoms are managed with symptomatic treatment and are expected to resolve over a short period.

Common side effects

Frequently reported tolerability concerns

  • Abdominal discomfort or cramping may occur.
  • Nausea may occur.
  • Vomiting may occur.
  • Dizziness may occur.
  • Flushing may occur.
  • Sweating may occur.
  • An urge to defecate may occur.
  • Diarrhea may occur less commonly.
  • Headache may occur less commonly.
  • A bitter taste in the mouth may occur less commonly.
  • Shortness of breath may occur less commonly.
  • Pain at the injection site may occur less commonly.
  • Tremor of the limbs may occur less commonly.
  • Sneezing may occur less commonly.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Anaphylaxis and other serious hypersensitivity reactions have been reported during or within an hour of sincalide administration.
  • Transient reduced tone of the lower esophageal sphincter can cause acid reflux during and shortly after the procedure.
  • Transient delayed gastric emptying can occur, which may affect a concurrent upper gastrointestinal imaging study.
  • Stimulated gallbladder contraction could theoretically dislodge small gallstones, causing them to lodge in the cystic or common bile duct, though this risk is considered minimal at recommended doses.
  • Seek urgent medical attention for wheezing, difficulty breathing, swelling of the face or throat, or signs of a severe allergic reaction during or after the injection.

Use with caution

Situations requiring closer assessment

  • Use with caution in patients with suspected duodenal, gastric, or pyloric ulcers, or gastrointestinal bleeding or bowel ulceration.
  • Use with caution when a concurrent upper gastrointestinal series is planned, since sincalide can transiently delay gastric emptying.
  • Use with caution when a barium enema examination is also planned, since sincalide increases bowel motility and can make the examination more difficult to perform.
  • Use with caution in patients with known small gallstones, given the small theoretical risk of stone migration into the bile ducts.
  • Use with caution in patients with sulfite sensitivity, even though the formulation's trace sulfite content should not prevent use when the test is clinically needed; appropriate medical support for a possible reaction should be available.
  • Use with caution in patients previously exposed to sincalide, since sensitization, although not reported, remains a theoretical possibility.

Contraindications

Situations where therapy may be inappropriate

  • Contraindicated in patients with known hypersensitivity to sincalide or to any non-medicinal ingredient in the formulation.
  • Contraindicated in patients with known hypersensitivity to sulfites, since the product contains sodium metabisulfite.
  • Contraindicated in situations where a fatty meal would be inappropriate, including acute pancreatitis, acute cholecystitis, cystic or common bile duct obstruction, gallbladder infection or empyema, small gallbladder stones, appendicitis, bowel perforation, peritonitis, a bleeding or perforating peptic ulcer, pyloric stenosis, mechanical bowel obstruction, or an acute abdomen in general.

Drug interactions

Clinically relevant combinations

  • Formal drug interaction studies have not been conducted with sincalide.
  • Drugs that stimulate or inhibit gallbladder motility or contraction may interfere with the gallbladder's response to sincalide; consider whether such drugs should be held before testing.
  • Medications affecting smooth muscle tone or pancreatic secretion could theoretically alter the results of sincalide-stimulated diagnostic testing, so recent relevant medication use should be reviewed before the procedure.

Food interactions

Meal-related administration

  • Sincalide is given by intravenous injection in a monitored clinical or radiology setting, so the empty-stomach/with-food distinction that applies to oral medicines does not apply; however, patients are typically asked to fast before sincalide-stimulated gallbladder or pancreatic function testing, since a recent meal can itself cause gallbladder contraction and confound the results.

Time of administration

Practical scheduling

  • Sincalide is administered as a single injection or infusion at the time of the diagnostic procedure, timed and dosed by the healthcare team performing the test; it is not a medicine taken on a regular home schedule.

Storage

Product handling

  • Store unreconstituted Kinevac vials at room temperature (15-30°C).
  • After reconstitution, the solution may be refrigerated for up to 24 hours, after which any unused portion must be discarded.

Patient take-away

Key counselling points for a quick closing summary

  • Sincalide is a diagnostic agent given as an injection to help doctors visualize your gallbladder or test your pancreatic function; it is not a medicine you take regularly at home.
  • Common effects such as brief stomach cramping, nausea, or flushing during or shortly after the injection are usually mild and pass quickly.
  • Tell the healthcare team performing your test about any allergies, especially to sulfites, and about any digestive conditions you have.
  • Seek immediate medical attention for any signs of a severe allergic reaction during or shortly after your test.

References

Source material and product information

  1. Health Canada Product Monograph — Sincalide

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.